Lilly Terminates Alzheimer’s Drug Trial, Citing Abnormal Liver Tests
Eli Lilly’s Phase II study for an investigational drug for Alzheimer’s disease has been terminated due to abnormal liver biochemical
Source: Health News
Posted in: AICHC News
Leave a Comment (0) ↓